Literature DB >> 27446570

MIB-1 labeling index, Ki-67, is an indicator of invasive intraductal papillary mucinous neoplasm.

Tatsuo Shimura1, Yasuhide Kofunato2, Ryo Okada2, Rei Yashima2, Koji Okada3, Kenichiro Araki3, Yasuo Hosouchi4, Hiroyuki Kuwano3, Seiichi Takenoshita2.   

Abstract

Despite strict criteria for the observation of intraductal papillary mucinous neoplasm (IPMN), it remains difficult to distinguish invasive IPMN from non-invasive IPMN. The aim of the present study was to identify an indicator of invasive IPMN. The present study retrospectively evaluated 53 patients (28 with non-invasive and 25 with invasive IPMN) who underwent resection of IPMN, and examined the usefulness of the MIB-1 labeling index as an indicator of invasive IPMN. The MIB-1 labeling indexes in patients with invasive IPMN were significantly higher compared with those with non-invasive IPMN (P<0.001). A receiver operating characteristic curve revealed that the area under the curve was 0.822. These results suggested that a cut-off level for the MIB-1 labeling index should be set to 15.5% to distinguish invasive from non-invasive IPMN. A multivariate analysis using a logistic regression model revealed the MIB-1 labeling index (hazard ratio, 18.692; 95% confidential interval, 4.171-83.760; P<0.001) and the existence of mural nodules (hazard ratio, 6.187, 95% confidential interval, 1.039-36.861; P=0.045) were predictive factors for invasive IPMN. However, no statistically significant differences were observed between patients with a lower MIB-1 labeling index and patients with a higher MIB-1 labeling index (P=0.798). The MIB-1 labeling index must be considered as a candidate for the classification of IPMN.

Entities:  

Keywords:  IPMN; Ki-67; MIB-1; invasive IPMN; mural nodule

Year:  2016        PMID: 27446570      PMCID: PMC4950762          DOI: 10.3892/mco.2016.908

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  23 in total

Review 1.  International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas.

Authors:  Masao Tanaka; Suresh Chari; Volkan Adsay; Carlos Fernandez-del Castillo; Massimo Falconi; Michio Shimizu; Koji Yamaguchi; Kenji Yamao; Seiki Matsuno
Journal:  Pancreatology       Date:  2006       Impact factor: 3.996

2.  Objective quantification of the Ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods.

Authors:  Laura H Tang; Mithat Gonen; Cyrus Hedvat; Irvin M Modlin; David S Klimstra
Journal:  Am J Surg Pathol       Date:  2012-12       Impact factor: 6.394

3.  Immunohistochemical expression of 14-3-3 sigma protein in intraductal papillary-mucinous tumor and invasive ductal carcinoma of the pancreas.

Authors:  Toshiyuki Okada; Norihiro Masuda; Yasuyuki Fukai; Tatsuo Shimura; Yasuji Nishida; Yasuo Hosouchi; Kenji Kashiwabara; Takashi Nakajima; Hiroyuki Kuwano
Journal:  Anticancer Res       Date:  2006 Jul-Aug       Impact factor: 2.480

4.  Cyst growth rate predicts malignancy in patients with branch duct intraductal papillary mucinous neoplasms.

Authors:  Mee Joo Kang; Jin-Young Jang; Soo Jin Kim; Kyoung Bun Lee; Ji Kon Ryu; Yong-Tae Kim; Yong Bum Yoon; Sun-Whe Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2010-09-17       Impact factor: 11.382

5.  Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas.

Authors:  S Fritz; T Hackert; U Hinz; W Hartwig; M W Büchler; J Werner
Journal:  Br J Surg       Date:  2010-10-14       Impact factor: 6.939

6.  Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas.

Authors:  M Sugiyama; Y Izumisato; N Abe; T Masaki; T Mori; Y Atomi
Journal:  Br J Surg       Date:  2003-10       Impact factor: 6.939

7.  Is it necessary to follow patients after resection of a benign pancreatic intraductal papillary mucinous neoplasm?

Authors:  Jin He; John L Cameron; Nita Ahuja; Martin A Makary; Kenzo Hirose; Michael A Choti; Richard D Schulick; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang
Journal:  J Am Coll Surg       Date:  2013-02-06       Impact factor: 6.113

8.  Nuclear expression of STAT5 in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Tatsuki R Kataoka; Tatsuya Ioka; Yoshitane Tsukamoto; Makiko Matsumura; Shingo Ishiguro; Yasuko Nishizawa
Journal:  Int J Surg Pathol       Date:  2007-07       Impact factor: 1.271

9.  Phosphorylated Akt/PKB controls cell growth and apoptosis in intraductal papillary-mucinous tumor and invasive ductal adenocarcinoma of the pancreas.

Authors:  Shuho Semba; Toshiyuki Moriya; Wataru Kimura; Mitsunori Yamakawa
Journal:  Pancreas       Date:  2003-04       Impact factor: 3.327

10.  Immunohistochemical analyses of E-cadherin, beta-catenin, CD44s, and CD44v6 expressions, and Ki-67 labeling index in intraductal papillary mucinous neoplasms of the pancreas and associated invasive carcinomas.

Authors:  Akira Okimura; Hiroshi Hirano; Takashi Nishigami; Shigemitsu Ueyama; Shiro Tachibana; Yoshikazu Fukuda; Koji Yamanegi; Hideki Ohyama; Nobuyuki Terada; Keiji Nakasho
Journal:  Med Mol Morphol       Date:  2009-12-24       Impact factor: 2.309

View more
  2 in total

Review 1.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: Current Understanding and Future Directions for Stratification of Malignancy Risk.

Authors:  Annabelle L Fonseca; Kimberly Kirkwood; Michael P Kim; Anirban Maitra; Eugene J Koay
Journal:  Pancreas       Date:  2018-03       Impact factor: 3.327

2.  Interplay of stromal tumor-infiltrating lymphocytes, normal colonic mucosa, cancer-associated fibroblasts, clinicopathological data and the immunoregulatory molecules of patients diagnosed with colorectal cancer.

Authors:  Łukasz Zadka; Mariusz Chabowski; Damian Grybowski; Aleksandra Piotrowska; Piotr Dzięgiel
Journal:  Cancer Immunol Immunother       Date:  2021-02-24       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.